Medical treatment in thyroid eye disease in 2020

Volume: 105, Issue: 3, Pages: 299 - 305
Published: May 23, 2020
Abstract
Thyroid eye disease (TED) affects 25% of patients with Graves’ hyperthyroidism, where 1 in 20 patients has active, moderate-to-severe disease that will require medical treatment for reducing TED activity and severity. Intravenous corticosteroid has been the mainstay of treatment for active moderate-to-severe TED. With improved understanding of the pathophysiology of TED, immunotherapy targeting different molecular pathways including T cells, B...
Paper Details
Title
Medical treatment in thyroid eye disease in 2020
Published Date
May 23, 2020
Volume
105
Issue
3
Pages
299 - 305
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.